Trials / Unknown
UnknownNCT03214302
The Incidence of Postpartum Hepatitis in Pregnant Women With Chronic Hepatitis B Virus Infection
The Incidence of Postpartum Hepatitis in Pregnant Women With High HBVDNA Loads
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 560 (estimated)
- Sponsor
- Beijing Ditan Hospital · Academic / Other
- Sex
- Female
- Age
- 20 Years – 35 Years
- Healthy volunteers
- Accepted
Summary
The majority of childbearing age women with hepatitis B virus infection were still in the immune tolerance period. Our recent research had shown that most puerperae after delivery had elevated ALT level. However, there is no withdrawal time recommendations after childbirth at present.Through the study of hepatitis occurrence after delivery and drug withdrawal, the investigators explore the withdrawal time of antiviral treatment during pregnancy.
Detailed description
Most of childbearing age women with hepatitis B virus infection were still in the immune tolerance period. Our recent research had shown that most puerperae after delivery had elevated ALT level, and 11.5% of patients with HBV DNA positive would lead to deterioration of liver function. Meanwhile, the highest peak of ALT level could occur in 2 weeks after delivery, then it would dropped to a low point in 4-5 weeks. However, there is no withdrawal time recommendations after childbirth at present.The aim of our study is to investigate the changes of serological indexes, the changing rule of the liver function, hepatitis status, and its correlation with antiviral therapy in pregnant women with HBV infection after delivery, and then explore the withdrawal time of antiviral treatment during pregnancy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate was used for the experimental group of pregnancy women in the 32 weeks during pregnancy |
Timeline
- Start date
- 2017-01-01
- Primary completion
- 2019-12-30
- Completion
- 2019-12-30
- First posted
- 2017-07-11
- Last updated
- 2017-07-13
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03214302. Inclusion in this directory is not an endorsement.